Multiple Sclerosis

Stem cell treatment for Multiple sclerosis or MS

Multiple Sclerosis (MS) is a disease in which the nerves of the central nervous system (brain and spinal cord) degenerate. Myelin, which provides a covering or insulation for nerves, improves the conduction of impulses along the nerves and also is important for maintaining the health of the nerves. In multiple sclerosis, inflammation causes the myelin to disappear.

Consequently, the electrical impulses that travel along the nerves decelerate, that is, become slower. In addition, the nerves themselves are damaged. As more and more nerves are affected, a person experiences a progressive interference with functions that are controlled by the nervous system such as vision, speech, walking, writing, and memory.

Usually, a person is diagnosed with multiple sclerosis between 20 and 50 years of age, but multiple sclerosis has been diagnosed in children and in the elderly. Multiple sclerosis is twice as likely to occur in Caucasians as in any other group. Women are twice as likely as men to be affected by multiple sclerosis earlier in life.

We use stem cell treatment for MS with umbilical cord mesenchymal stem cells (UCMSC). The most successful results of the stem cell therapy for MS are reported in patients with relapsing-remitting multiple sclerosis (successful rate up to 95%) but in other types of multiple sclerosis, patients also report improvement of their condition (successful rate up to 87%).*

The goal of stem cell treatment for multiple sclerosis is to interrupt the immune aggression against patient’s own nervous system in order to eliminate the main mechanism of disease development. Adult stem cell therapy using umbilical cord mesenchymal stem cells (UCMSC) transplantation may stop disease progression and lead to regression of the neurological symptoms. No relapses were reported during the follow-up period (up to 5 years after the treatment).*